FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080895533> ?p ?o ?g. }

• W2080895533 endingPage "420" @default.
• W2080895533 startingPage "413" @default.
• W2080895533 abstract "Objectives Acetazolamide-challenged perfusion magnetic resonance imaging (MRI) has been shown as a method for assessment of cerebrovascular reserve (CVR) capacity in patients with atherosclerotic steno-occlusive disease of internal carotid artery. We have assessed the feasibility of the acetazolamide-challenged perfusion MRI for evaluating CVR in symptomatic patients with severe middle cerebral artery (MCA) stenosis (≥70%) by comparison with the acetazolamide-challenged technetium-99m-hexamethylpropyleneamine oxime (HMPAO) single-photon emission computed tomography (SPECT). Methods Seventeen prospectively enrolled patients with symptomatic unilateral MCA stenosis underwent technetium-99m-hexamethylpropyleneamine oxime SPECT and perfusion MRI without and with acetazolamide challenge, respectively. Acetazolamide-challenged SPECT and perfusion MRI were compared quantitatively by Region of interest (ROI) analysis. Results At all ROIs, there were no significant differences in percent change between SPECT and perfusion MRI. Patients with impaired CVR showed significant decreases in the percent changes of respective cerebral blood flow (P=.016) and respective cerebral blood volume (P=.029). Conclusion Acetazolamide-challenged perfusion MRI is feasible for evaluating CVR in symptomatic patients with severe MCA stenosis quantitatively." @default.
• W2080895533 created "2016-06-24" @default.
• W2080895533 creator A5003308463 @default.
• W2080895533 creator A5006889833 @default.
• W2080895533 creator A5012108207 @default.
• W2080895533 creator A5013554036 @default.
• W2080895533 creator A5014555716 @default.
• W2080895533 creator A5027011598 @default.
• W2080895533 creator A5038515968 @default.
• W2080895533 creator A5043264501 @default.
• W2080895533 creator A5047156899 @default.
• W2080895533 creator A5050319187 @default.
• W2080895533 creator A5055136874 @default.
• W2080895533 creator A5072249558 @default.
• W2080895533 creator A5074233271 @default.
• W2080895533 date "2011-11-01" @default.
• W2080895533 modified "2023-09-25" @default.
• W2080895533 title "Acetazolamide-challenged perfusion magnetic resonance imaging for assessment of cerebrovascular reserve capacity in patients with symptomatic middle cerebral artery stenosis: comparison with technetium-99m-hexamethylpropyleneamine oxime single-photon emission computed tomography" @default.
• W2080895533 cites W1970693385 @default.
• W2080895533 cites W1980205676 @default.
• W2080895533 cites W2004556881 @default.
• W2080895533 cites W2016796516 @default.
• W2080895533 cites W2028856260 @default.
• W2080895533 cites W2035264537 @default.
• W2080895533 cites W2049847542 @default.
• W2080895533 cites W2054494992 @default.
• W2080895533 cites W2059302638 @default.
• W2080895533 cites W2068691217 @default.
• W2080895533 cites W2089034720 @default.
• W2080895533 cites W2148064340 @default.
• W2080895533 cites W2168840624 @default.
• W2080895533 cites W4240994847 @default.
• W2080895533 doi "https://doi.org/10.1016/j.clinimag.2011.03.001" @default.
• W2080895533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22040783" @default.
• W2080895533 hasPublicationYear "2011" @default.
• W2080895533 type Work @default.
• W2080895533 sameAs 2080895533 @default.
• W2080895533 citedByCount "11" @default.
• W2080895533 countsByYear W20808955332013 @default.
• W2080895533 countsByYear W20808955332014 @default.
• W2080895533 countsByYear W20808955332015 @default.
• W2080895533 countsByYear W20808955332016 @default.
• W2080895533 countsByYear W20808955332018 @default.
• W2080895533 countsByYear W20808955332020 @default.
• W2080895533 countsByYear W20808955332021 @default.
• W2080895533 countsByYear W20808955332022 @default.
• W2080895533 crossrefType "journal-article" @default.
• W2080895533 hasAuthorship W2080895533A5003308463 @default.
• W2080895533 hasAuthorship W2080895533A5006889833 @default.
• W2080895533 hasAuthorship W2080895533A5012108207 @default.
• W2080895533 hasAuthorship W2080895533A5013554036 @default.
• W2080895533 hasAuthorship W2080895533A5014555716 @default.
• W2080895533 hasAuthorship W2080895533A5027011598 @default.
• W2080895533 hasAuthorship W2080895533A5038515968 @default.
• W2080895533 hasAuthorship W2080895533A5043264501 @default.
• W2080895533 hasAuthorship W2080895533A5047156899 @default.
• W2080895533 hasAuthorship W2080895533A5050319187 @default.
• W2080895533 hasAuthorship W2080895533A5055136874 @default.
• W2080895533 hasAuthorship W2080895533A5072249558 @default.
• W2080895533 hasAuthorship W2080895533A5074233271 @default.
• W2080895533 hasConcept C126322002 @default.
• W2080895533 hasConcept C126838900 @default.
• W2080895533 hasConcept C135691158 @default.
• W2080895533 hasConcept C143409427 @default.
• W2080895533 hasConcept C146957229 @default.
• W2080895533 hasConcept C154281038 @default.
• W2080895533 hasConcept C157767197 @default.
• W2080895533 hasConcept C164705383 @default.
• W2080895533 hasConcept C2775841333 @default.
• W2080895533 hasConcept C2777405951 @default.
• W2080895533 hasConcept C2778064278 @default.
• W2080895533 hasConcept C2779902710 @default.
• W2080895533 hasConcept C2780007028 @default.
• W2080895533 hasConcept C2780441642 @default.
• W2080895533 hasConcept C2989005 @default.
• W2080895533 hasConcept C4375535 @default.
• W2080895533 hasConcept C541997718 @default.
• W2080895533 hasConcept C71924100 @default.
• W2080895533 hasConceptScore W2080895533C126322002 @default.
• W2080895533 hasConceptScore W2080895533C126838900 @default.
• W2080895533 hasConceptScore W2080895533C135691158 @default.
• W2080895533 hasConceptScore W2080895533C143409427 @default.
• W2080895533 hasConceptScore W2080895533C146957229 @default.
• W2080895533 hasConceptScore W2080895533C154281038 @default.
• W2080895533 hasConceptScore W2080895533C157767197 @default.
• W2080895533 hasConceptScore W2080895533C164705383 @default.
• W2080895533 hasConceptScore W2080895533C2775841333 @default.
• W2080895533 hasConceptScore W2080895533C2777405951 @default.
• W2080895533 hasConceptScore W2080895533C2778064278 @default.
• W2080895533 hasConceptScore W2080895533C2779902710 @default.
• W2080895533 hasConceptScore W2080895533C2780007028 @default.
• W2080895533 hasConceptScore W2080895533C2780441642 @default.
• W2080895533 hasConceptScore W2080895533C2989005 @default.
• W2080895533 hasConceptScore W2080895533C4375535 @default.
• W2080895533 hasConceptScore W2080895533C541997718 @default.
• W2080895533 hasConceptScore W2080895533C71924100 @default.
• W2080895533 hasIssue "6" @default.
• W2080895533 hasLocation W20808955331 @default.

• next